Search research articles
Contact Us
Filters
Showing results (671-680 of 703) with videos related to
Page
of 71
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
E L Mayer, F-C Bidard, Y H Park, et al.
Journal of Geriatric Oncology
|
September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
Rachel A Freedman, Tianyu Li, Mina S Sedrak, et al.
Journal of the National Cancer Institute
|
October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Genes and Immunity
|
April 26, 2013
Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3
W Zhang, K Y Hui, A Gusev, et al.
Nature Genetics
|
April 27, 2023
Single duplex DNA sequencing with CODEC detects mutations with high sensitivity
Jin H Bae, Ruolin Liu, Eugenia Roberts, et al.
The New England Journal of Medicine
|
June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast Cancer
François-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Journal of the National Cancer Institute
|
April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy
Christina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.
Nature Communications
|
December 15, 2025
Single cell proteomic analysis defines discrete neutrophil functional states in human glioblastoma
Pranvera Sadiku, Alejandro J Brenes, Rupert L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Erica L Mayer, Yue Ren, Nikhil Wagle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Page
of 71
Search research articles
Search
Showing results (671-680 of 703) with videos related to
Sort By:
Page
of 71
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
E L Mayer, F-C Bidard, Y H Park, et al.
Journal of Geriatric Oncology
|
September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
Rachel A Freedman, Tianyu Li, Mina S Sedrak, et al.
Journal of the National Cancer Institute
|
October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Genes and Immunity
|
April 26, 2013
Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3
W Zhang, K Y Hui, A Gusev, et al.
Nature Genetics
|
April 27, 2023
Single duplex DNA sequencing with CODEC detects mutations with high sensitivity
Jin H Bae, Ruolin Liu, Eugenia Roberts, et al.
The New England Journal of Medicine
|
June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast Cancer
François-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Journal of the National Cancer Institute
|
April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy
Christina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.
Nature Communications
|
December 15, 2025
Single cell proteomic analysis defines discrete neutrophil functional states in human glioblastoma
Pranvera Sadiku, Alejandro J Brenes, Rupert L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Erica L Mayer, Yue Ren, Nikhil Wagle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Page
of 71